1.68
price up icon4.35%   0.07
pre-market  Pre-market:  1.68  
loading
Pepgen Inc stock is traded at $1.68, with a volume of 135.72K. It is up +4.35% in the last 24 hours and down -1.18% over the past month. PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
See More
Previous Close:
$1.61
Open:
$1.59
24h Volume:
135.72K
Relative Volume:
0.05
Market Cap:
$43.48M
Revenue:
-
Net Income/Loss:
$-87.23M
P/E Ratio:
-0.5657
EPS:
-2.97
Net Cash Flow:
$-82.77M
1W Performance:
+26.32%
1M Performance:
-1.18%
6M Performance:
-79.59%
1Y Performance:
-85.80%
1-Day Range:
Value
$1.56
$1.69
1-Week Range:
Value
$1.28
$1.78
52-Week Range:
Value
$0.8801
$19.30

Pepgen Inc Stock (PEPG) Company Profile

Name
Name
Pepgen Inc
Name
Phone
703-456-8000
Name
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Name
Employee
81
Name
Twitter
Name
Next Earnings Date
2024-11-08
Name
Latest SEC Filings
Name
PEPG's Discussions on Twitter

Compare PEPG with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PEPG
Pepgen Inc
1.68 43.48M 0 -87.23M -82.77M -2.97
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.47 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.76 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.51 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.61 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.16 24.89B 3.81B -644.79M -669.77M -6.24

Pepgen Inc Stock (PEPG) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-16-24 Downgrade BofA Securities Neutral → Underperform
Jul-31-24 Downgrade BofA Securities Buy → Neutral
Dec-21-22 Initiated H.C. Wainwright Buy

Pepgen Inc Stock (PEPG) Latest News

pulisher
Apr 22, 2025

PepGen Inc. CEO Makes Bold Stock Purchase! - TipRanks

Apr 22, 2025
pulisher
Apr 21, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph

Apr 21, 2025
pulisher
Apr 15, 2025

Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Apr 15, 2025
pulisher
Apr 09, 2025

PepGen Inc.’s CEO Makes Bold Stock Purchase! - TipRanks

Apr 09, 2025
pulisher
Apr 09, 2025

PepGen president and CEO McArthur buys shares worth $47,724 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 09, 2025

PepGen president and CEO McArthur buys shares worth $47,724 - Investing.com

Apr 09, 2025
pulisher
Apr 08, 2025

PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 05, 2025

PepGen stock plunges to 52-week low of $1.14 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

PepGen stock plunges to 52-week low of $1.14 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

PepGen (NASDAQ:PEPG) Stock Price Down 14.4% – Time to Sell? - Defense World

Apr 04, 2025
pulisher
Apr 02, 2025

PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace

Apr 02, 2025
pulisher
Apr 01, 2025

PepGen Announces Appointment of Two New Directors to its Board - BioSpace

Apr 01, 2025
pulisher
Mar 31, 2025

PepGen Appoints Lisa Wyman and Mitchell Finer to its Board of Directors - citybiz

Mar 31, 2025
pulisher
Mar 31, 2025

PepGen Inc. Expands Board with New Appointments - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

PepGen names two new directors to board - TipRanks

Mar 31, 2025
pulisher
Mar 28, 2025

PepGen CMO Mellion resigns, effective April 4 - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

PepGen CMO Mellion resigns, effective April 4 By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 26, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen IncPEPG - Bluefield Daily Telegraph

Mar 26, 2025
pulisher
Mar 18, 2025

PEPG ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of PepGen Inc. Shareholders Who Lost Money - ACCESS Newswire

Mar 18, 2025
pulisher
Mar 10, 2025

PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire

Mar 10, 2025
pulisher
Mar 10, 2025

PepGen Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsPEPG - ACCESS Newswire

Mar 10, 2025
pulisher
Mar 05, 2025

PepGen Inc. Faces Clinical Trial Challenges and Competitive Pressures Leading to Sell Rating - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

What Do Analysts Think Will Happen To PepGen Inc (NASDAQ: PEPG) - Stocks Register

Mar 05, 2025
pulisher
Mar 05, 2025

PepGen to Participate in Upcoming March 2025 Investor Conferences - BioSpace

Mar 05, 2025
pulisher
Mar 04, 2025

PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls - Benzinga

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

Boston biotech's stock drops after Duchenne trial pause - The Business Journals

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen to pause CONNECT2-EDO51 study - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen slumps after pausing mid-stage study of Duchenne drug - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen pauses phase 2 DMD study to review earlier trial data - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD -March 04, 2025 at 08:18 am EST - Marketscreener.com

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen stock slides after trial pause (PEPG:NASDAQ) - Seeking Alpha

Mar 04, 2025
pulisher
Mar 04, 2025

Pepgen Announces Update To Phase 2 Connect2-Edo51 Study In Patients With DMD - TradingView

Mar 04, 2025
pulisher
Mar 04, 2025

PepGen to Participate in Upcoming Investor Conferences - Business Wire

Mar 04, 2025
pulisher
Mar 04, 2025

AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable

Mar 04, 2025
pulisher
Mar 03, 2025

PepGen Sees Fastest Weekly Retail Following Growth Among Biotech Stocks: What's Behind The Buzz? - Asianet Newsable

Mar 03, 2025
pulisher
Mar 03, 2025

PepGen (PEPG) to Release Quarterly Earnings on Wednesday - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

PEPG Stock Price and Chart — NASDAQ:PEPG - TradingView

Mar 02, 2025

Pepgen Inc Stock (PEPG) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.54
price up icon 2.04%
$68.96
price down icon 2.60%
$32.03
price up icon 1.07%
$36.70
price up icon 10.44%
$120.54
price up icon 4.97%
biotechnology ONC
$256.16
price up icon 2.82%
Cap:     |  Volume (24h):